NCT07561827 The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusion (PSF) Surgery
| NCT ID | NCT07561827 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University of California, San Francisco |
| Condition | Adolescent Idiopathic Scoliosis (AIS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2025-06-06 |
| Primary Completion | 2027-01-26 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 42 participants in total. It began in 2025-06-06 with a primary completion date of 2027-01-26.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to better understand the efficacy of an erector spinae plane block (ESPB) in pain management for children with Adolescent Idiopathic Scoliosis or Neuromuscular Scoliosis undergoing Posterior Spinal Fusion surgery. The study team is trying to find out if receiving the ESPB leads to less pain and less need for pain medication after surgery. The ESPB involves an injection of a local anesthetic, ropivacaine, into your child's back muscles to help block pain signals.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Adolescent Idiopathic Scoliosis (AIS) or neuromuscular scoliosis * Undergoing Posterior Spinal Fusion (PSF) Surgery Exclusion Criteria: * Patients with forms of scoliosis other than AIS or NM Scoliosis. * Patients undergoing a spinal deformity correction surgery other than Posterior Spinal Fusion Surgery * Allergy or other contraindication to erector spinae plane block (ESPB) with Ropivacaine patients who are taking pre-operative opioids
Contact & Investigator
Ishaan Swarup, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT07561827 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Adolescent Idiopathic Scoliosis (AIS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07561827 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 42 participants.
Is NCT07561827 currently recruiting?
Yes, NCT07561827 is actively recruiting participants. Contact the research team at tripta.rughwani@ucsf.edu for enrollment information.
Where is the NCT07561827 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT07561827 clinical trial?
NCT07561827 is sponsored by University of California, San Francisco. The principal investigator is Ishaan Swarup, MD at University of California, San Francisco. The trial plans to enroll 42 participants.